OCTOBER 28 – NOVEMBER 1, 2018
SHERATON NEW ORLEANS AND NEW ORLEANS MARRIOTT, NEW ORLEANS, LOUISIANA USA

ASTMH 2018
AMERICAN SOCIETY OF TROPICAL MEDICINE & HYGIENE
**MONDAY, OCTOBER 29TH**

**ORAL PRESENTATION**

The burden of skin disease and eye disease due to onchocerciasis in Africa for 2015 and 2025

Session 2 - Filariasis: Epidemiology and control I

DNDi author(s): Belén Pedrique, Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

8:30AM – 8:45AM

Sheraton – Waterbury (2nd Floor)

**POSTER PRESENTATION**

The Chagas disease study landscape: Preliminary analysis of a systematic review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform

Session A - 573

DNDi author(s): Eric Chatelain, DNDi, Geneva, Switzerland

Fabiana Barreira, Sergio Sosa Estani, DNDi Latin America, Rio de Janeiro, Brazil

12:00PM – 1:45PM

Marriott – Grand Ballroom (3rd Floor)
A single-center, first-in-human, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability and pharmacokinetics of escalating single doses of emodepside (BAY44-4400) in healthy male subjects

Session A - 534

DNDi author(s): Jean Yves A. Gillon, Karen Dequatre Cheeseman, Sophie Delhomme, Claudia Peña Rossi, Frederic Monnot, Nathalie Strub-Wourgaft, Rob Don, DNDi, Geneva, Switzerland

Capacity building platform for clinical and operational research on Human African trypanosomiasis

Session A - 567

DNDi author(s): Florent Mbo Kuikumbi, DNDi, Kinshasa, Democratic Republic of Congo
Olaf Valverde, DNDi, Geneva, Switzerland

Novel 3-dimensional optical scanning in the assessment of patients with mycetoma

Session 28 - Clinical tropical medicine

DNDi author(s): Eduard E. Zijlstra, DNDi, Geneva, Switzerland

SOCIAL MEDIA

DNDi is sharing stories of people affected by neglected diseases and the researchers, scientists, and health workers who strive to develop better treatments.

Follow us on social media to join the conversation, and share your story with #IamTropMed

@dndi.org @DNDi @dndi @drugsforneglecteddiseases

VISIT US AT BOOTH #318
From R&D to access for sleeping sickness elimination: Innovative public-private partnerships for new tools

Co-Chairs: Victor Kande Betu Kumeso, NTD Director, Ministry of Health, Kinshasa, Democratic Republic of Congo
Luc Kuykens, Senior Vice-President Global Health Programs, Sanofi, Gentilly, France
Bernard Pécoul, Executive Director, DNDi

Session introduction: Victor Kande Betu Kumeso, NTD Director, Ministry of Health, Kinshasa, Democratic Republic of Congo
Discussion facilitation: Luc Kuykens, Senior Vice President Global Health Programs, Sanofi, Gentilly, France
Bernard Pécoul, Executive Director, DNDi

An alternative model for drug development: The story of fexinidazole, Nathalie Strub-Wourgaft, Director of Neglected Tropical Diseases, DNDi, Geneva, Switzerland

Working in partnership for sleeping sickness elimination: Using new technologies, Florent Mbo Kuikumbi, HAT Platform Coordinator, DNDi, Kinshasa, Democratic Republic of Congo

Finding every last case: The role of diagnostics in HAT elimination, Veerle Lejon, National Reference Centre for Parasitology, Research Director, Institut de Recherche pour le Développement, Montepellier, France

Importance of the development of an oral treatment for sleeping sickness through public-private partnership, Luc Kuykens, Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

Striving towards HAT elimination in South Sudan: An operational perspective, Laurence Flevaud, Operational Centre Barcelona-Athens, Médecins Sans Frontières, Barcelona, Spain

Monitoring HAT elimination: Plans for validation, Gerardo Priotto, Department of Control of Neglected Tropical Diseases, Word Health Organization, Geneva, Switzerland
TUESDAY, OCTOBER 30TH

POSTER PRESENTATION

Prioritizing pathogens to support diagnostic product development for febrile illness management: A novel yet pragmatic approach

Session B - 1225

DNDi author(s): Isabela Ribeiro, DNDi, Geneva, Switzerland

POSTER PRESENTATION

Evaluation of point-of-care tests for visceral leishmaniasis diagnosis in Kenya

Session B - 1271

DNDi author(s): Monique Wasunna, DNDi Africa, Nairobi, Kenya
Overcoming challenges in screening and diagnosis of Chagas disease

Symposium Organizer: Sergio Sosa Estani, DNDi Latin America, Rio de Janeiro, Brazil

Co-Chair: Colin Forsyth, DNDi North America, New York, NY, United States

Serological diagnostic and Trypanosoma cruzi diversity, Claudia Herrera, Tulane University, New Orleans, LA, United States

Latest Developments in Biomarkers Research, Eric Chatelain, DNDi, Geneva, Switzerland

Community-based screening of Chagas disease in the USA: Boston’s Strong Hearts Program, Julia Koehler, Boston Children’s Hospital, Boston, MA, United States

Implementation of a simplified diagnostic algorithm in an endemic area of Colombia, Colin J. Forsyth, DNDi North America, New York, NY, United States
ORAL PRESENTATION

Pharmacokinetic-pharmacodynamic assessment of the safety of fexinidazole for the treatment of Human African trypanosomiasis

Session 109 - Kinetoplastida: Diagnosis, treatment and vaccine development

DNDi author(s): Nathalie Strub-Wourgraft, Antoine Tarral
DNDi, Geneva, Switzerland

ORAL PRESENTATION

Modeling and simulations of fexinidazole treatment regimen for human African Trypanosoma brucei gambiense trypanosomiasis (g-HAT) and their successful clinical application in adult and child patients

Session 109 - Kinetoplastida: Diagnosis, treatment and vaccine development

DNDi author(s): Antoine Tarral, DNDi, Geneva, Switzerland

POSTER PRESENTATION

Determination of fexinidazole effect on QTc in healthy volunteers and human African Trypanosoma brucei gambiense trypanosomiasis (g-HAT) patients using concentration-response modelling

Session C - LB-5526

DNDi author(s): Antoine Tarral, DNDi, Geneva, Switzerland

POSTER PRESENTATION

Sequential versus classical designs for early phase drug trials against visceral leishmaniasis

Session C - LB-5527

DNDi author(s): Fabiana Alves, Manica Balasegaram, Séverine Blesson, DNDi, Geneva, Switzerland
Raymond Omollo, Monique Wasunna
DNDi Africa, Nairobi, Kenya
ORAL PRESENTATION

Oxfendazole treatment has a macrofilaricidal efficacy against the filarial nematode *Litomosoides sigmodontis in vivo* and inhibits *Onchocerca gutturosa* adult worm motility *in vitro*

Session 172 – Filariasis: Clinical

DNDi author(s): Ivan Scandale, DNDi, Geneva, Switzerland

VISIT US AT BOOTH #318
We’ll be showing films from the HuffPost “Out of Sight” series on sleeping sickness and river blindness. The sleeping sickness film was shot at DNDi clinical sites in the Democratic Republic of Congo, and follows the trip of one of our doctors to develop new treatments. The river blindness film was also shot in Congo (and in Nigeria), and deals with the challenges and successes of eliminating this disease. challenges of and progress toward eliminating three of those diseases.

Watch at our booth!
DNDi is sharing stories of people affected by neglected diseases and the researchers, scientists, and health workers who strive to develop better treatments.

Follow us on social media to join the conversation, and share your story with #IamTropMed

Photo credits: Neil Brandvold/DNDi, Xavier Vahad/DNDi, Angela Boatwright/DNDi